These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of potential inhibitors of HER2 targeting breast cancer-a structure-based drug design approach. Singh G; Al-Fahad D; Al-Zrkani MK; Chaudhuri TK; Soni H; Tandon S; Narasimhaji CV; Azam F; Patil R J Biomol Struct Dyn; 2024 Sep; 42(15):8184-8201. PubMed ID: 37565730 [TBL] [Abstract][Full Text] [Related]
3. Identification of HER2 inhibitors from curcumin derivatives using combination of Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338 [TBL] [Abstract][Full Text] [Related]
4. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach. Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395 [TBL] [Abstract][Full Text] [Related]
5. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents. Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701 [TBL] [Abstract][Full Text] [Related]
6. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach. Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911 [TBL] [Abstract][Full Text] [Related]
7. Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach. Alrumaihi F J Biomol Struct Dyn; 2024 Aug; 42(12):6269-6279. PubMed ID: 37424103 [TBL] [Abstract][Full Text] [Related]
8. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach. Agarwal S; Kashaw SK J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248 [TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors. Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133 [TBL] [Abstract][Full Text] [Related]
10. Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319 [TBL] [Abstract][Full Text] [Related]
11. Exploring the Synergistic Mechanism of AP2A2 Transcription Factor Inhibition via Molecular Modeling and Simulations as a Novel Computational Approach for Combating Breast Cancer: In Silico Interpretations. Niranjan V; Setlur AS; K C; Kumkum S; Dasgupta S; Singh V; Desai V; Kumar J Mol Biotechnol; 2024 Sep; 66(9):2497-2521. PubMed ID: 37747672 [TBL] [Abstract][Full Text] [Related]
12. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease. Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340 [TBL] [Abstract][Full Text] [Related]
13. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367 [TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205 [TBL] [Abstract][Full Text] [Related]
15. Computational evaluation of bioactive compounds from Dairo G; Ilesanmi A; Balogun T; Ward M; Soendergaard M; Determan J J Biomol Struct Dyn; 2023; 41(24):15610-15624. PubMed ID: 36935102 [TBL] [Abstract][Full Text] [Related]
16. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines. Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601 [TBL] [Abstract][Full Text] [Related]
17. Computational analyses of curcuminoid analogs against kinase domain of HER2. Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037 [TBL] [Abstract][Full Text] [Related]
18. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors. Al-Anazi M; Al-Najjar BO; Khairuddean M Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058 [TBL] [Abstract][Full Text] [Related]